Studies have shown that CT can be effective in both colorectal cancer screening (including screening for large polyps) and lung cancer screening.
Colorectal cancer
CT colonography (also known as virtual colonoscopy) can be used to screen for both large colorectal polyps and colorectal tumors. CT colonography uses the same dose of radiation that is used in standard CT of the abdomen and pelvis, which is about 10 millisieverts (mSv). (By comparison, the estimated average annual dose received from natural sources of radiation is about 3 mSv.) As with standard colonoscopy, a thorough cleansing of the colon is performed before this test. During the examination, air or carbon dioxide is pumped into the colon to expand it for better viewing.
The National CT Colonography Trial, an NCI-sponsored clinical trial, found that the accuracy of CT colonography is similar to that of standard colonoscopy. CT colonography is less invasive than standard colonoscopy and has a lower risk of complications. However, if polyps or other abnormal growths are found on CT colonography, a standard colonoscopy is usually performed to remove them.
Whether CT colonography can help reduce the death rate from colorectal cancer is not yet known, and most insurance companies (and Medicare) do not currently reimburse the costs of this procedure. Also, because CT colonography can produce images of organs and tissues outside the colon, it is possible that noncolorectal abnormalities may be found. Some of these "extracolonic" findings will be serious, but many will not be, leading to unnecessary additional tests and surgeries.
Lung cancer
The NCI-sponsored National Lung Screening Trial (NLST) showed that people aged 55 to 74 years with a history of heavy smoking are 20% less likely to die from lung cancer if they are screened with low-dose helical CT than if they are screened with standard chest x-rays. (Previous studies had shown that screening with standard chest x-rays does not reduce the death rate from lung cancer.) The estimated amount of radiation in a low-dose helical CT procedure is 1.5 mSv. Those who have never smoked tobacco products are considered to be at too low a risk of lung cancer to benefit from lung cancer screening.
Despite the effectiveness of low-dose helical CT for lung cancer screening in heavy smokers, the NLST identified risks as well as benefits. For example, people screened with low-dose helical CT had a higher overall rate of false-positive results (that is, findings that appeared to be abnormal even though no cancer was present) than those screened with standard x-rays. NCI’s Patient and Physician Guide: National Lung Screening Trial provides more information on the benefits and harms.
The benefits of helical CT in screening for lung cancer may vary, depending on how similar someone is to the people who participated in the NLST. The benefits may also be greater for those with a higher lung cancer risk, and the harms may be more pronounced for those who have more medical problems (like heart or other lung disease), which could increase problems arising from biopsies and other surgery. However, because low-dose lung CT can produce images of organs and tissues outside the lung, it is possible that nonpulmonary abnormalities such as renal or thyroid masses may be found. As with extracolonic findings from CT colonography, some such findings will be serious, but many will not.
Under the Affordable Care Act, all Marketplace health plans, and many other health plans, must cover lung cancer screening with low-dose CT as a preventive care benefit for adults ages 55 to 80 years who have a 30 pack-year smoking history (e.g., smoked one pack of cigarettes per day for 30 years or two packs of cigarettes per day for 15 years) and are either a current smoker or a former smoker who quit within the last 15 years. People who think they might qualify for screening with low-dose helical CT should discuss the appropriateness and the benefits and risks of lung cancer screening with their doctors. They should also check with their health insurance company to determine whether this screening is covered by their insurance plan.
Medicare covers the costs of annual lung cancer screening with low-dose CT in beneficiaries considered to be at increased risk based on their smoking history. Annual screening is covered for Medicare beneficiaries who are between 55 and 77 years old; have no signs or symptoms of lung cancer; are either a current smoker or have quit smoking within the last 15 years; have smoked an average of one pack a day for 30 years (i.e., 30 pack years); and receive the screening and low-dose CT scan at a Medicare-approved radiology facility. Medicare coverage includes a prescreening counseling visit with the health professional who wrote the order to review the benefits and risks of lung cancer screening.